RxSight, Inc. (NASDAQ:RXST) Shares Bought by LPL Financial LLC

LPL Financial LLC boosted its position in shares of RxSight, Inc. (NASDAQ:RXST) by 1.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 33,640 shares of the company’s stock after buying an additional 582 shares during the period. LPL Financial LLC owned 0.10% of RxSight worth $969,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in RXST. Ameritas Investment Partners Inc. increased its holdings in shares of RxSight by 39.2% in the first quarter. Ameritas Investment Partners Inc. now owns 1,907 shares of the company’s stock valued at $32,000 after purchasing an additional 537 shares during the period. UBS Group AG increased its holdings in shares of RxSight by 413.6% in the fourth quarter. UBS Group AG now owns 5,388 shares of the company’s stock valued at $68,000 after purchasing an additional 4,339 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of RxSight in the third quarter valued at approximately $69,000. Barclays PLC increased its holdings in shares of RxSight by 533.3% in the fourth quarter. Barclays PLC now owns 5,529 shares of the company’s stock valued at $70,000 after purchasing an additional 4,656 shares during the period. Finally, BNP Paribas Arbitrage SNC acquired a new position in shares of RxSight in the third quarter valued at approximately $78,000. Institutional investors and hedge funds own 66.51% of the company’s stock.

Insiders Place Their Bets

In other RxSight news, Director Bakker Juliet Tammenoms sold 100,000 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $27.13, for a total transaction of $2,713,000.00. Following the sale, the director now directly owns 894,313 shares in the company, valued at $24,262,711.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other RxSight news, Director Bakker Juliet Tammenoms sold 100,000 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was sold at an average price of $27.13, for a total transaction of $2,713,000.00. Following the sale, the director now directly owns 894,313 shares in the company, valued at $24,262,711.69. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Shweta Maniar sold 4,292 shares of the business’s stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $28.06, for a total value of $120,433.52. Following the sale, the director now owns 24,947 shares in the company, valued at $700,012.82. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 143,417 shares of company stock worth $3,997,054. 21.13% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Oppenheimer boosted their target price on RxSight from $29.00 to $34.00 and gave the company an “outperform” rating in a report on Tuesday, August 8th. Needham & Company LLC dropped their target price on RxSight from $36.00 to $30.00 and set a “buy” rating on the stock in a report on Friday, November 10th.

RxSight Price Performance

RxSight stock opened at $27.53 on Friday. RxSight, Inc. has a 1-year low of $10.29 and a 1-year high of $33.77. The company has a market cap of $987.23 million, a PE ratio of -15.91 and a beta of 0.79. The stock’s 50 day moving average price is $25.88 and its 200 day moving average price is $27.05.

RxSight (NASDAQ:RXST) last posted its quarterly earnings results on Thursday, November 9th. The company reported ($0.35) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.07. The firm had revenue of $22.20 million for the quarter, compared to the consensus estimate of $20.81 million. RxSight had a negative return on equity of 39.77% and a negative net margin of 71.87%. On average, equities research analysts anticipate that RxSight, Inc. will post -1.55 EPS for the current fiscal year.

RxSight Company Profile

RxSight, Inc, an ophthalmic medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.